← All trials
NCT02978443
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Georgetown UniversityLead sponsor
- Melanoma Research Foundation Breakthrough ConsortiumCollaborator
- Bristol-Myers SquibbCollaborator
- University of Colorado, DenverCollaborator
- University of California, San FranciscoCollaborator
- Vanderbilt UniversityCollaborator
- Columbia UniversityCollaborator
- University of PittsburghCollaborator
- Yale UniversityCollaborator
- Northwestern UniversityCollaborator
- University of South FloridaCollaborator
- University of Texas at HoustonCollaborator
- Cornell UniversityCollaborator
- Harvard UniversityCollaborator
- Georgetown UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.